Persistent therapeutic effect of repeated injections of Onabotulinum toxin A in refractory Bladder Pain Syndrome / Interstitial Cystitis

• Type: Summary of Presentation in an International Conference
• Date: 2011

Authors

Rui Pinto (Author) FMUP; Tiago Lopes (Author) FMUP; Joao Silva (Author) FMUP; Carlos Silva (Author) FMUP; Francisco Cruz (Author) FMUP; Paulo Dinis (Author) FMUP

Conference proceedings International

Title: The Journal of Urology

Pages: 379-379

Persistent therapeutic effect of repeated injections of Onabotulinum toxin A in refractory Bladder Pain Syndrome / Interstitial Cysytitis

Washington DC - USA, 14 a 19 de Maio de 2011

Indexing

Pubmed / Medline

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

CORDIS: Health sciences > Medical sciences > Medicine > Urology

Other information

Abstract (EN): INTRODUCTION AND OBJECTIVES: To evaluate the persistence of the therapeutic effect of repeated intra-trigonal injection of Onabotulinum toxin A in patients with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) refractory to first line treatment. METHODS: Fourteen women with BPS/IC refractory to first line treatment received 4 consecutive intra-trigonal injections of Onabotulinum toxin A. Patients were treated under general anaesthesia. With a rigid cystoscope, 100 U of Onabotulinum toxin A were injected in 10 trigonal sites, each receiving 10 U in 1 ml of saline. All patients were discharged under prophylactic antibiotic. The therapeutic effect was evaluated by a 3-day voiding chart, O’Leary-Sant Score (OSS), QoL from IPSS, and by pain visual analogue scale (0 –10) before treatment and every 3 months after each injection. Voiding dysfunction and urinary tract infections (UTIs) were accessed every 3 months. Duration of each injection was determined by the moment patients requested another treatment. RESULTS: Patients had a mean age of 42 y, and a BPS/IC ESSIC classification of 2a (1), 2b (1), 2c (4), 3a (1), 3b (2) and 3c (5). Mean values at baseline were: pain score, 5.91.8; urinary frequency, 16.45.3; OSS, 28.86.3; and QoL, 50.9. All patients reported subjective improvement following each injection. Decreases in pain score, urinary frequency, OSS and QoL after each treatment are shown in Table 1. Each treatment provided symptomatic relief for a period between 9 –10 months. No cases of voiding dysfunction were reported and 5 patients had UTIs after Onabotulinum toxin A injection (2 after 2nd treatment, 1 after 3rd treatment and 2 after 4th treatment). CONCLUSIONS: This study suggests that intra-trigonal injection of 100 U of Onabotulinum toxin A is safe, effective and has maintained effect after repeated injections in refractory BPS/IC. Mean duration of the symptomatic improvement was superior to 9 months after treatment.

Language: English

Type (Professor's evaluation): Scientific